

Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

FBRC:004USC1/HYL

Serial No.

09/576,101

Applicant

Andreas Suhrbier, et al.

Filing Date:

May 22, 2000

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
PNT	B1	WO 95/30015	11-9-95	PCT			
	B2	WO 9524926	9-21-95	PCT			
	B3	WO 94/26785	11-24-94	PCT			
	B4	WO 94/18234	8-18-94	PCT			
	B5	WO 94/00153	1-6-94	PCT			
	B6	WO 94/00150	1-6-94	PCT			
	B7	WO 93/25575	12-23-93	PCT			
	B8	WO 93/22343	11-11-93	PCT			
	B9	WO 93/19092	9-30-93	PCT			Yes
	B10	0 532 090 A2	3-17-93	PCT			
	B11	WO 93/01831	2-4-93	PCT			
✓	B12	WO 90/11085	10-4-90	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
PNT	C1	Aichele, et al., "Antiviral Cytotoxic T Cell Response Induced by In Vivo Priming with a Free Synthetic Peptide", <i>J. Exp. Med.</i> 171:1815-1820, 1990

1657820.1

EXAMINER:

DATE CONSIDERED:

8/31/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
FBRC:004USC1/HYLSerial No.
09/576,101Applicant
Andreas Suhrbier, et al.Filing Date:
May 22, 2000Group:
1644U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

RECEIVED

JAN 31 2001

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Pst	C2	Alexander-Miller, <i>et al.</i> , "Alloreactive Cytotoxic T Lymphocytes Generated in the Presence of Viral-Derived Peptides Show Exquisite Peptide and MHC Specificity", <i>The Journal of Immunology</i> 151:1-10, 1993
	C3	Andrew, <i>et al.</i> , "Vaccinia Virus Recombinants Expressing the SA11 Rotavirus VP7 Glycoprotein Gene Induce Serotype-Specific Neutralizing Antibodies", <i>J. Virol.</i> 61:1054-1060, 1987
	C4	Apolloni, <i>et al.</i> , "Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus", <i>Eur. J. Immunol.</i> 22:183-189, 1992
	C5	Araget, <i>et al.</i> , "Dominant Selection of an Invariant T Cell Antigen Receptor in Response to Persistent Infection by Epstein-Barr Virus", <i>J. Exp. Med.</i> , 108:2335-2340, 1994
	C6	Arnold, <i>et al.</i> , "Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules", <i>Nature</i> 360:171-174, 1992
	C7	Baer, <i>et al.</i> , "DNA sequence and expression of the B95-8 Epstein-Barr virus genome, <i>Nature</i> 310:207 - 211, 1984
	C8	Boyle, <i>et al.</i> , "Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses", <i>Gene</i> 35:169-177, 1985
	C9	Brooks, <i>et al.</i> , "Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide" <i>J. Exp. Med.</i> , 178/3 (879-887) 1993
	C10	Burrows, <i>et al.</i> , "An Epstein-Barr Virus-Specific Cytotoxic T-Cell Epitope Present on A- and B-Type Transformants", <i>Journal of Virology</i> 64:3974-3976, 1996
	C11	Burrows, <i>et al.</i> , "Identification of a Naturally Occurring Recombinant Epstein-Barr Virus Isolate from New Guinea That Encodes both Type 1 and Type 2 Nuclear Antigen Sequences", <i>Journal of Virology</i> 7:4829-4833, 1996
✓	C12	Burrows, <i>et al.</i> , "Unusually high frequency of Epstein- Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: Implications for virus evolution" <i>Journal of Virology</i> 70:2490-2496. 1996

1657820.1

EXAMINER:

DATE CONSIDERED:

8/31/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
FBRC:004USC1/HYLSerial No.
09/576,101Applicant
Andreas Suhrbier, et al.Filing Date:
May 22, 2000Group:
1644U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
PNH	C13	Burrows, <i>et al.</i> , "Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3." <i>J Gen Virol</i> 75:2489-93, 1994
	C14	Burrows, <i>et al.</i> , "An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein - Barr virus CTL epitope: implications for graft-versus-host disease. <i>J. Exp. Med.</i> 179:1155-61, 1994
	C15	Burrows, <i>et al.</i> , "The specificity of recognition of a cytotoxic T lymphocyte epitope", <i>Eur. J. Immunol</i> 22:191-195, 1992
	C16	Burrows, <i>et al.</i> , "Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing", <i>Immunology</i> 76:174-175, 1992
	C17	Burrows, <i>et al.</i> , "An Epstein-Barr Virus-Specific Cytotoxic T Cell Epitope in EBV Nuclear Antigen 3 (EBNA 3)", <i>J. Exp. Med.</i> 171:345-349, 1990
	C18	Burrows, <i>et al.</i> , "Patterns of Reactivity of Epstein-Barr Virus Specific T Cells in A-Type Donor Cultures after Reactivation with Autologous A- or B- Type Transformants", <i>Cellular Immunology</i> 127:47-55, 1990
	C19	Buseyne, <i>et al.</i> , "Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24(gag) protein" <i>J. Virol USA</i> , 67:694-702, 1993
	C20	Carbone, <i>et al.</i> , "Induction of Cytotoxic T. Lymphocytes by Primary In Vitro Stimulation with Peptides", <i>J. Exp. Med.</i> 167:1767-1779, 1988
	C21	de Campos-Lima, <i>et al.</i> , "T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein - Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues", <i>J. Exp. Med.</i> 179:1297-305, 1994
	C22	Driscoll, <i>et al.</i> , "MHC-linked LMP gene products specifically alter peptidase activities of the proteasome", <i>Nature</i> 365:262-264, 1993
✓	C23	Eisenlohr, <i>et al.</i> , "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes", <i>J. Exp. Med.</i> , 175:481-487, 1992

1657820.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
FBRC:004USC1/HYLSerial No.
09/576,101

List of Patents and Publications for Applicant's

Applicant
Andreas Suhrbier, et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
May 22, 2000Group:
1644U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Pnt	C24	Elliott, <i>et al.</i> , "Induction of Protective Cytotoxic T Lymphocytes Using a Nona-peptide and a Human-Compatible Adjuvant", <i>Nature (Lond.)</i> 337:651, 1989
	C25	Epping, <i>et al.</i> , "An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in <i>Plasmodium falciparum</i> ", <i>Mol. Biochem. Parasitol.</i> 28:1-10, 1988
	C26	Gaczynska, <i>et al.</i> , " γ -Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes", <i>Nature</i> 365:264-267, 1993
	C27	Gao, <i>et al.</i> , "Priming of Influenza Virus-Specific Cytotoxic T Lymphocytes Vivo By Short Synthetic Peptides", <i>The Journal of Immunology</i> 147:3268-3273, 1991
	C28	Goldberg and Kennith, "Proteolysis, proteasomes and antigen presentation", <i>Nature</i> 357:375-379, 1992
	C29	Ho, <i>et al.</i> , "Site-directed mutagenesis by overlap extension using the polymerase chain reaction", <i>Gene</i> 77:51-59, 1989
	C30	Ho, Monto, "Role of Specific Cytotoxic Lymphocytes in Cellular Immunity Against Murine Cytomegalovirus", <i>Infection and Immunity</i> , 27: (3) 767-776, 1980
	C31	Ikeda, <i>et al.</i> , "Protective activity of the lipid A analogue GLA-60 against murine cytomegalovirus infection in immunodeficient mice", <i>Journal of General Virology</i> , 74:1399-1403, 1993
	C32	Johnson, <i>et al.</i> , "Recognition of a Highly Conserved Region of Human Immunodeficiency Virus Type 1 gp120 by an HLA-Cw4-Restricted Cytotoxic T-Lymphocyte Clone", <i>J. Virol</i> 67:438-445, 1993
	C33	Kara, <i>et al.</i> , "Chemical characterization of the parasitophorous vacuole membrane antigen QF 116 from <i>Plasmodium falciparum</i> ", <i>Mol. Biochem. parasitol.</i> 38:19-24, 1990
✓	C34	Kast, <i>et al.</i> , "Protection against lethal Asendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide", <i>Proc. Natl. Acad. Sci. USA</i> , 88:2283-2287, 1991

1657820.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

A: 110314(#1657820 VI - FBRC:004USC1 FORM 1449 (#1657820))

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
FBRC:004USC1/HYLSerial No.
09/576,101Applicant
Andreas Suhrbier, et al.Filing Date:
May 22, 2000Group:
1644U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Pst	C35	Khanna, <i>et al.</i> , "Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance", <i>Virology</i> 214:633-637, 1995
	C36	Khanna, <i>et al.</i> , "Immune regulation in Epstein-Barr virus-associated diseases", <i>Microbiol Rev</i> 59:387-405, 1995
	C37	Khanna, <i>et al.</i> , "EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2." <i>J. Immunol</i> , 150:5154-62, 1993
	C38	Khanna, <i>et al.</i> , "Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection", <i>J. Immunol Methods</i> 164:41-49, 1993
	C39	Khanna, <i>et al.</i> , "Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development", <i>J. Exp. Med.</i> , 176:169-176, 1992
	C40	Khanna, <i>et al.</i> , "Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells", <i>Immunology</i> , 74:504-10, 1991
	C41	Kozak, M., "Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes", <i>Cell</i> 44:283-292, 1986
	C42	Kyaw-Tanner, <i>et al.</i> , "Epstein-Barr Virus-Specific Cytotoxic T Cell Response in Cardiac Transplant Recipients", <i>Transplantation</i> 57:1611-1617, 1994
	C43	Lee, <i>et al.</i> , "Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population", <i>Eur. J. Immunol</i> 25:102-110, 1995
	C44	Lee, <i>et al.</i> , "HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2", <i>J. Virol.</i> 67:7428-7435, 1993
✓	C45	Lees, <i>et al.</i> , "The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.", <i>Virology</i> 195:578-586, 1993

1657820.1

EXAMINER:

DATE CONSIDERED:

8/31/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

A: 110314(#1657820 v1 - FBRC:004USC1 FORM 1449 (#1657820))

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

FBRC:004USC1/HYL

Serial No.

09/576,101

Applicant

Andreas Suhrbier, et al.

Filing Date:

May 22, 2000

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
PNT	C46	Levitsky, <i>et al.</i> , "The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein- Barr virus nuclear antigen 4", <i>J. Exp. Med.</i> 183:915-926, 1996
	C47	Michalek, <i>et al.</i> , "A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation", <i>Nature</i> 363:552-554, 1993
	C48	Misko, <i>et al.</i> , "Failure of Epstein - Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen", <i>Clin. exp. Immunol.</i> 87:65-70, 1992
	C49	Misko, <i>et al.</i> , "Cytotoxic T lymphocyte discrimination between type A Epstein- Barr virus transformants is mapped to an immunodominant epitope in EBNA 3", <i>J. Gen. Virol.</i> 72:405-409, 1991
	C50	Misko, <i>et al.</i> , "T lymphocytes in infectious mononucleosis; Effect on IL-2 on the outgrowth of Epstein-Barr virus-infected cells", <i>Immunol. Cell Biol.</i> 67:49-55, 1989
	C51	Momburg, <i>et al.</i> , "Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation", <i>Nature</i> 360:174-177, 1992
	C52	Morioka, <i>et al.</i> , "A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients", <i>J. Immunol.</i> 153:5650-5658, 1994
	C53	Moss, <i>et al.</i> , "Potential antigenic targets on Epstein- Barr virus-associated tumours and the host response", <i>Ciba Found Symp.</i> , 187: 4-13; discussion 13-20, 1994
	C54	Moss, <i>et al.</i> , "T Cell-T Cell Killing Is Induced by Specific Epitopes: Evidence for an Apoptotic Mechanism", <i>J. Exp. Med.</i> 173:681-686, 1991
	C55	Moss, <i>et al.</i> , "Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants", <i>Nature</i> 331:719-721, 1988
✓	C56	Moss, <i>et al.</i> , "Calcium Concentration Defines Two Stages in Transformation of Lymphocytes By Epstein-Barr Virus", <i>Int. J. Cancer</i> 33:587-590, 1984

1657820.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

A: 110314(#1657820 v1 - FBRC:004USC1 FORM 1449 (#1657820))

Form PTO-1449 (modified)

Atty. Docket No.

FBRC:004USC1/HYL

Serial No.

09/576,101

List of Patents and Publications for Applicant

Applicant

Andreas Suhrbier, et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

May 22, 2000

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
PSH	C57	Moss, <i>et al.</i> , "Epstein-Barr Virus Specific T-Cell Response in Nasopharyngeal Carcinoma Patients, <i>Int. J. Cancer</i> 32:301-305, 1983
	C58	Moss, <i>et al.</i> , "A Comparison of Epstein-Barr Virus-Specific T-Cell Immunity in Malaria-Endemic and -Nonendemic Regions of Papua New Guinea, <i>Int. J. Cancer</i> , 31:727-732, 1983
	C59	Murray, <i>et al.</i> , "Identification of Target Antigens for the Human Cytotoxic T Cell Response to Epstein-Barr Virus (EBV): Implications for the Immune Control of EBV-positive Malignancies", <i>J. Exp. Med.</i> 176:157-168, 1992
	C60	Murray, <i>et al.</i> , "Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses", <i>Proc. Natl. Acad. Sci. USA</i> 87:2906-2910, 1990
	C61	Nonacs, <i>et al.</i> , Mechanisms of Mouse Spleen Dendritic Cell Function in the Generation of Influenza-specific, Cytolytic T Lymphocytes, <i>J. Exp. Med.</i> 176:519-529, 1992
	C62	Oldstone, <i>et al.</i> , "Vaccination To Prevent Persistent Viral Infection", <i>J. Virol.</i> 67:4372-4378, 1993
	C63	Pither, <i>et al.</i> , "Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera", <i>J. Gen. Virol.</i> 73:1409-1415, 1992
	C64	Renia, <i>et al.</i> , "in vitro activity of CD4 ⁺ and CD8 ⁺ T lymphocytes from mice immunized with a synthetic malaria peptide", <i>Proc. Natl. Acad. Sci. USA</i> , 88:7963-7967, 1991
	C65	Rowe, <i>et al.</i> , "Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression", <i>Eur. J. Immunol.</i> 25:1374-1384 1995
	C66	Rowe, <i>et al.</i> , Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins", <i>J. Virol.</i> 63:1031-1039, 1989
✓	C67	Scalzo, <i>et al.</i> , "Induction of Protective Cytotoxic T Cells to Murine Cytomegalovirus by Using a Nonapeptide and a Human-Compatible Adjuvant (Montanide ISA-720)", <i>Journal of Virology</i> , 69:(2)1306-1309, 1995

1657820.1

EXAMINER:

DATE CONSIDERED:


8/31/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

A: 110314(#1657820 v1 - FBRC:004USC1 FORM 1449 (#1657820))

Form PTO-1449 (modified)



Att'y. Docket No.

FBRC:004USC1/HYL

Serial No.

09/576,101

List of Patents and Publications for Applicant's

Applicant

Andreas Suhrbier, et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

May 22, 2000

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

RECEIVED

JAN 31 2001

TECH CENTER 1600/2200

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
PNK	C68	Schmidt, <i>et al.</i> "Nonresponsiveness to an immunodominant Epstein- Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies", <i>Proc. Natl. Acad. Sci. U S A</i> 88:9478-9482, 1991
	C69	Schulz, <i>et al.</i> , "peptide-induced antiviral protection by cytotoxic T cells", <i>Proc. Natl. Acad. Sci. USA</i> 88:991-993, 1991
	C70	Thomson, <i>et al.</i> , "Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design", <i>Proc. Natl. Acad. Sci.</i> 92:5845-5489, 1995
	C71	Ulmer, <i>et al.</i> , "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein", <i>Science</i> 259:1745-1748, 1993
	C72	Wallace, <i>et al.</i> "Identification of two T-cell epitopes on the candidate Epstein- Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones", <i>J. Virol.</i> 65:3821-3828, 1991
	C73	White, <i>et al.</i> , "Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1", <i>Virology</i> 219:489-492, 1996
	C74	Whitton, <i>et al.</i> , "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge", <i>J. Virol</i> 67:348-352, 1993
	C75	Widmann, <i>et al.</i> , "T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides", <i>Journal of Immunological Methods</i> 155:95-99, 1992
	C76	Widmann, <i>et al.</i> , "Differential Stability of Antigenic MHC Class I-Restricted Synthetic Peptides", <i>The Journal of Immunology</i> 147:3745-3751, 1991
	C77	Yasutomi, <i>et al.</i> , "Synthetic Peptide in Mineral Oil adjuvant Elicits Simian Immunodeficiency Virus-Specific CD8+ Cytotoxic T Lymphocytes in Rhesus Monkeys", <i>The Journal of Immunology</i> 141:5096-5105, 1993
✓	C78	Zhou, <i>et al.</i> , "In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides", <i>Journal of Immunological Methods</i> 153:193-200, 1992

1657820.1

EXAMINER:

DATE CONSIDERED:

8/31/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

A: 110314(#1657820 VI - FBRC:004USC1 FORM 1449 (#1657820))